Please assess the completion status of the following clinical trial:

Trial Title: Companion: Sensor-based Two-way Communication for Physical Activity in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 60 years and above- This intervention study focusses on this population demographic.~* Participants have a body mass index greater than 25 kg/m2- This threshold for BMI is used to classify an adult as overweight or obese~* No conditions preventing participation in physical activity lasting 10 to 30 min- Such conditions will limit prescription of physical activity/exercise components of the training program and that promoted using Companion.~* Have a smart phone- The absence of a smart phone will limit the ability of remote communication with the study participant using Companion.~Exclusion Criteria:~* Engage in structured physical activity for more than 2 days/week lasting 30 min/session- Physically active participants will not be representative of typical adults \>60 y. Being active prior to study participation may mask the effects of the intervention.~* Regularly use any assistive device for walking- Use of an assistive device would limit the ability to engage in prescribed physical activity. Future work can be tailored for sub-groups in the demographic being studied.~* Likely to alter medications pertaining to cardiovascular or metabolic health- Altering medications during the study will influence change in selected outcome measures.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: NO_INTERVENTION): Control group will engage in a 16-week supervised exercise program and then be followed-up after 24 weeks
- Treatment (Type: EXPERIMENTAL): Treatment group will engage in a 16-week supervised exercise program and then be followed-up after 24 weeks. In addition, the Companion will be deployed in the treatment group only.

Based on this trial design, predict the completion outcome and termination type (if applicable).